Mandate

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.

The transaction is subject to customary regulatory approvals.

Sertion is a leading Nordic specialist in complex pipework services, serving a broad range of commercial, industrial and infrastructure end-markets where reliability, technical expertise and safety are essential. The group operates across the full pipework value chain – from engineering and prefabrication to installation, service and ongoing operations – and delivers its services through 16 local entities and approximately 1,000 employees in Sweden, Norway and Denmark. Sertion is headquartered in Stockholm, has a turnover of approximately SEK 3 billion and is active in the design, installation and servicing of water, heating and sanitation systems, industrial piping and energy gas solutions.

Vinge’s team primarily consisted of Christina Kokko, Desirée Hagenfeldt, Elsie Nassar, Nicolina Lavdas, Anna Neubüser and Lucas Eriksson (M&A), David Olander (Competition Law and FDI), Linn Adelwald and William Carlberg Johansson (Banking and Finance), as well as Emelie Schoning and Jasmina Skandrani (Project Assistants).

Related

Vinge advises Greenfood

Vinge advises Greenfood in connection with the divestment of its Fresh Produce business to Dole.
October 21, 2026

Vinge has advised Investor in connection with acquisition of shares in EQT

Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026